DiaMedica Promotes Mark Robbins to Executive Vice President

MINNEAPOLIS, MINNESOTA--(Marketwired - July 10, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.

Dr. Robbins joined DiaMedica in December 2012 as Vice President, Clinical and Regulatory Affairs. He will continue to oversee the Company's clinical development efforts.

"We're excited to promote Mark to the role of Executive Vice President. He has made significant contributions to DiaMedica, each demonstrating an unwavering commitment to advancing our current product portfolio, in addition to identifying other potential product opportunities," said Rick Pauls, President & CEO. "His continued leadership and vision will help ensure DiaMedica is able to achieve its longer term goal of commercialization of its products."

Dr. Robbins has over 30 years of experience in biopharmaceutical drug development with broad therapeutic experience in endocrine/metabolic, cardiology, neurology, dermatology, and oncology. Dr. Robbins has developed and successfully implemented regulatory/clinical strategies leading to 11 successful NDA/BLA approvals. Prior to joining DiaMedica, Dr. Robbins spent 15 years with Upsher-Smith Laboratories, advancing to Executive Vice President, Legal, Scientific and Technical Operations, Chief Scientific Officer and Assistant Secretary, where he oversaw the clinical and regulatory strategies for several drugs ranging from R&D to manufacturing and Phase I to Phase III. Previous to this role, Dr. Robbins spent 13 years at Mallinckrodt Group, Inc., advancing to Director of Medical Affairs.

About DiaMedica

DiaMedica is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical-stage product, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing DM204, a preclinical-stage monoclonal antibody, for the treatment of type 2 diabetes.

DiaMedica's common shares are listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.